Welsh AMs call for greater awareness of GP Palliative Care Registers

Welsh AMs call for greater awareness of GP Palliative Care Registers

July 18 2018 Targets should be set to increase the number of people requiring palliative care to...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

NICE says to restrict antibiotics in COPD

NICE says to restrict antibiotics in COPD

July 13 2018 Draft guidance is calling for health professionals to consider the risk of...

NICE updates guideline on rheumatoid arthritis

NICE updates guideline on rheumatoid arthritis

July 13 2018 NICE has issued a new version of its guideline on the management of rheumatoid...

Community pharmacy option for antihypertensives referral sees little increase in GP workload

Community pharmacy option for antihypertensives referral sees little increase in GP workload

July 11 2018 Community pharmacy referrals for hypertensive patients under the New Medicines...

  • Welsh AMs call for greater awareness of GP Palliative Care Registers

    Welsh AMs call for greater awareness of GP Palliative Care Registers

    Wednesday, 18 July 2018 17:52
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:48
  • NICE says to restrict antibiotics in COPD

    NICE says to restrict antibiotics in COPD

    Friday, 13 July 2018 13:05
  • NICE updates guideline on rheumatoid arthritis

    NICE updates guideline on rheumatoid arthritis

    Friday, 13 July 2018 12:58
  • Community pharmacy option for antihypertensives referral sees little increase in GP workload

    Community pharmacy option for antihypertensives referral sees little increase in GP workload

    Wednesday, 11 July 2018 13:17

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

July 18 2018 Targets should be set to increase the number of people requiring palliative care to be included on General Practice Palliative Care Registers in Wales. There should also be measures to...
July 11 2018 Community pharmacy referrals for hypertensive patients under the New Medicines Service has not increased GP workload appreciably. Analysis of 131,419 patient records in England has...